CancerFax Insights
CancerFax NewsLetter
Welcome to our inaugural edition. This week brings remarkable news across multiple cancer types, an FDA approval in lung cancer with historic response rates, a first-in-30-years breakthrough for pancreatic cancer, a viral therapy rewriting the rules for brain tumors, and a body-wide immune response triggered by injecting a single tumor. We cover all four stories below.
Pancreatic Cancer · FDA Approval
On February 12, 2026, the FDA approved Optune Pax, a wearable device that delivers low-intensity alternating electric fields (Tumor Treating Fields, or TTFields) to the abdomen at 150 kHz, for patients with locally advanced pancreatic cancer. The device is used in combination with standard chemotherapy (gemcitabine + nab-paclitaxel).
Pancreatic cancer has one of the lowest 5-year survival rates of any major cancer. This approval marks the first genuinely new therapeutic modality for locally advanced disease in nearly three decades offering patients and oncologists an additional option where very few have existed.
Get involved
Looking for advanced treatment options?
CancerFax connects patients and caregivers with cutting-edge cancer treatments in China, India, and beyond, including CAR-T therapy, gene therapy, and clinical trials not available locally. Our team helps you navigate options, costs, and logistics.
CancerFax
Connecting cancer patients to advanced treatments worldwide.
[email protected] • cancerfax.com
Copyright @CancerFax 2026